Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acinar

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Acinar. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-002586-36 Sponsor Protocol Number: PACT-9 Start Date*: 2005-07-01
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: PEXG VERSUS PDXG IN LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA : RANDOMIZED, PHASE II STUDY.
    Medical condition: PANCREAS TUMOR TREATMENT
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001238-41 Sponsor Protocol Number: 2006-001238-41 Start Date*: 2007-01-04
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Phase II trial of Erlotinib in combination with increasing dose of gemcitabine given as fixed dose rate infusion in advanced pancreatic cancer.
    Medical condition: Patients with unresectable advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004236-40 Sponsor Protocol Number: I1-GOA-1 Start Date*: 2007-12-10
    Sponsor Name:Universitätsklinikum Ulm
    Full Title: Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer
    Medical condition: advanced metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005544-10 Sponsor Protocol Number: NIHRCDF Start Date*: 2012-04-10
    Sponsor Name:Imperial College London
    Full Title: Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10052996 Inhalation therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000674-30 Sponsor Protocol Number: 2013-000674-30 Start Date*: 2013-07-24
    Sponsor Name:AOU SAN LUIGI GONZAGA - SCDU ONCOLOGIA MEDICA
    Full Title: Multicenter clinical trial, randomized phase II "window of opportunity" which aims to test the biological activity of abiraterone acetate administered as neoadjuvant therapy in patients with prosta...
    Medical condition: PROSTATE CANCER PATIENTS WITH HIGH RISK
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005168-94 Sponsor Protocol Number: KKS-77-05 Start Date*: 2006-06-20
    Sponsor Name:Philipps-University of Marburg
    Full Title: Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer
    Medical condition: The aim is to evaluate the feasibility of the combined treatment of cetuximab and gemcitabine in patients with R0-resectable pancreatic cancer and to evaluate if the progression free survival can b...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-014548-13 Sponsor Protocol Number: PROTPROS Start Date*: 2009-09-18
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: Evaluation of chemopreventive effect of a galenic preparation, comparable to a food integrator, composed by seleniomethionine, lycopene and polyphenols (green tea epigallocatechingallate and catech...
    Medical condition: Patients with first prostate biopsy with diagnosis of ASAP (Atypical Small Acinar Proliferation) or multifocal (≥2 positive samples) HGPIN (High-Grade Prostatic Intraepithelial Neoplasia)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029037 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001781-32 Sponsor Protocol Number: MAPS Start Date*: 2007-06-14
    Sponsor Name:GISCAD
    Full Title: A randomized phase II study of gemcitabine/cisplatin with or without sorafenib to evaluate the efficacy and safety in patients with locally advanced or metastatic pancreatic cancer. MAPS trial
    Medical condition: Subjects enrolled in this study must have histologically confirmed locally advanced or metastatic pancreatic adenocarcinoma. They must not have been received a first-line chemotherapy. Presence of ...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10033609 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000486-33 Sponsor Protocol Number: T19/2021 Start Date*: 2022-03-21
    Sponsor Name:Turku University Hospital
    Full Title: 99mTc-MIP-1404 SPECT/CT for primary PROstate cancer STAging: comparative prospective, randomized trial to present guideline imaging
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001852-38 Sponsor Protocol Number: EFC10203 Start Date*: 2007-12-21
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A Multicenter, Open-Label, Randomized Study Comparing the Efficacy and Safety of S-1 as a Single Agent at 30 mg/m2 BID versus 5-FU Bolus Infusion for the Treatment of Patients with Metastatic Panc...
    Medical condition: Advanced Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033609 Pancreatic carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) SE (Completed) GR (Completed) DK (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005754-23 Sponsor Protocol Number: ASSTBS-FRADIO-SPA-2020 Start Date*: 2021-04-06
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA Trial)
    Medical condition: prostate acinar adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007453 Carcinoma of the prostate metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001201 Adenocarcinoma of the prostate stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007456 Carcinoma of the prostate stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036951 Prostatic cancer stage II LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036918 Prostate cancer stage II PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001202 Adenocarcinoma of the prostate stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007457 Carcinoma of the prostate stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036952 Prostatic cancer stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036919 Prostate cancer stage III PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005471-17 Sponsor Protocol Number: RASH Start Date*: 2012-05-08
    Sponsor Name:Klinikum der Universität München-Großhadern
    Full Title: Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors
    Medical condition: metastatic pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011992-61 Sponsor Protocol Number: EMR200066-003 Start Date*: 2009-10-05
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: Ensayo de fase II, aleatorizado, del inhibidor de MEK AS703026 o placebo en combinación con gemcitabina, en pacientes con cáncer de páncreas metastásico no tratados previamente con quimioterapia.
    Medical condition: Tratamiento de primera línea con AS703026 en combinación con gemcitabina del cáncer metastático de páncreas y /o tratamiento de segunda línea con AS703026 tras progresión con monoterapia de gemcita...
    Disease: Version SOC Term Classification Code Term Level
    9 10033577 Pancreas carcinoma recurrent LLT
    9 10033576 Pancreas carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) FR (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-005790-60 Sponsor Protocol Number: CL-SBP-101-04 Start Date*: 2022-08-05
    Sponsor Name:Panbela Therapeutics, Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
    Medical condition: Metastatic Pancreatic Ductal Adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Temporarily Halted) IT (Prematurely Ended) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000676-26 Sponsor Protocol Number: CAN-301-DE Start Date*: 2014-10-16
    Sponsor Name:Prima BioMed Ltd
    Full Title: A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed with Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients with Resected Stage...
    Medical condition: Maintenance treatment with Cvac in patients with resected stage I or stage II adenocarcinoma (cancer) of the pancreas
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003086-14 Sponsor Protocol Number: EFC6596 Start Date*: 2006-10-09
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel (XRP9881) Compared to Continuous Administration of 5-FU For The Treatment of Patients With Advanced Pancreatic Cancer Previousl...
    Medical condition: Advanced Pancreatic Cancer.
    Disease: Version SOC Term Classification Code Term Level
    11.1 10033604 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) DE (Completed) IT (Completed) GB (Completed) HU (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-004906-79 Sponsor Protocol Number: ESPAC-6 Start Date*: 2021-10-08
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg
    Full Title: An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemother...
    Medical condition: Resected pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033575 Pancreas cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002464-27 Sponsor Protocol Number: IEOS707/412 Start Date*: 2013-06-26
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients with solid tumors metastatic or relapsed, resistant/refractory to conventional therapy, using HLA-identical related donors or H...
    Medical condition: solid tumors metastatic or relapsed, resistant/refractory to conventional therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033612 Pancreatic carcinoma NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017760 Gastric cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000643-13 Sponsor Protocol Number: GI1612 Start Date*: 2016-09-15
    Sponsor Name:Herlev & Gentofte Hospital
    Full Title: A MULTINATIONAL, RANDOMIZED, PHASE II STUDY OF THE COMBINATION OF NAB-PACLITAXEL AND GEMCITABINE WITH OR WITHOUT IL-6R INHIBITOR, TOCILIZUMAB, AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVAN...
    Medical condition: LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033609 Pancreatic carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2008-006209-17 Sponsor Protocol Number: I2I-MC-JMMC Start Date*: 2011-07-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer
    Medical condition: Phase I: Patients with solid malignancy unlikely to benefit from approved therapies. Phase II: Patients with pancreatic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 25 21:19:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA